A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Tirasemtiv (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms VIGOR-ALS
- Sponsors Cytokinetics
- 02 Mar 2018 This trial has been completed in Netherlands.
- 06 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2017 According to a Cytokinetics media release, the company will seek advice from the academic leadership of VITALITY-ALS and its clinical investigators, regulatory authorities and other consultants before making decisions about continuing treatment with tirasemtiv in VIGOR-ALS.